Abstract In order to examine the relationship between local adenosine concentrations before, during, and after ischemia and the extent of ischemic myocardial damage, mea-
Introduction Methods
A substantial literature has accumulated which indicates that adenosine is cardioprotective. Exogenous administration of adenosine has been reported to improve functional recovery and reduce infarct size in a variety of models (10, 24, 26, 31) . Exogenous adenosine, however is also associated with potentially adverse side-effects such as bradycardia, atrioventricular dissociation, and hypotension (2) . Consequently, recent attention has been focused on manipulation of endogenous adenosine levels within ischemic myocardium, the objective being enhancement of local adenosine levels (or effects of adenosine) in a site and condition specific manner to minimize adverse sideeffects. Local concentrations and effects of endogenous adenosine have been manipulated pharmacologically (e.g., adenosine deaminase inhibitors, nucleoside transport inhibitors, AICA riboside) in a number of studies (7, 8, 13, 15) . Changes in endogenous adenosine levels may also be important in ischemic preconditioning, a nonpharmacologic means of enhancing ischemic tolerance. A potential common denominator for ischemic preconditioning and pharmacologic manipulation of adenosine metabolism may be the degree to which they both effect interstitial adenosine concentration in ischemic myocardium. Accordingly, the objective of the present study was to obtain serial estimates of myocardial interstitial adenosine levels during ischemia, to test the hypothesis that a relationship exists between myocardial protection and changes in interstitial adenosine concentrations. Data regarding the effects of adenosine deaminase inhibitors on endogenous adenosine levels and myocardial protection have been obtained in a dog model (27) , but no data have been reported from studies in the pig, a species characterized by very low native collateral investment (14) . However, studies from Schulz et al. have reported that the infusion of adenosine deaminase in swine reduces adenosine concentrations during low-flow ischemia (20, 21) , and abolishes the protective effects of ischemic preconditioning (20) , again suggesting a relationship between regional adenosine concentrations and ischemic tolerance. The microdialysis technique was used to sample interstitial adenosine concentration during ischemia produced by coronary occlusion alone or coronary occlusion preceded by interventions anticipated to alter local adenosine levels. The two interventions were ischemic preconditioning and pretreatment with tile adenosine deaminase inhibitor pentostatin (29) . Infarct size was used as the principal endpoint to define the effects of ischemia.
Experimental preparation
Experiments were performed in 30 isoflurane anesthetized Yucatan Micropigs of either sex, weighting between 15.5 and 20.5 kilograms. Animals were premedicated with ketamine (30 mg/kg IM) and atropine (0.05 mg/kg IM), then anesthesia was induced by isoflurane (4 % in oxygen) through a mask placed over the mouth and snout. When a surgical level of anesthesia was achieved, a tracheostomy was performed and a cuffed endotracheal tube was placed in the trachea. At this point the isoflurane concentration was reduced, and anesthesia was maintained with 1.0 -1.5 % isoflurane in oxygen. Mechanical ventilation (Halowell Model ~2000) with supplemental oxygen (1.2 L/min) was adjusted to maintain pH and PCOz within normal ranges, and PO2 in excess of 100 mmHg. Body temperature was monitored with a rectal probe and maintained as close to baseline temperature (37 ~ as possible with a recirculating water heating blanket.
The internal carotid artery and external jugular vein were cannulated with polyethylene catheters for aortic blood pressure measurement and fluid/drug administration, respectively. A midline sternotomy was performed and the heart was suspended in a pericardial cradle. A Millar micromanometer (Model ~PC350) was inserted through the apex of the left ventricle to measure left ventricular pressure, and the left atrial appendage was cannulated with a polyethylene catheter for measurement of left atrial pressure. The proximal left anterior descending (LAD) artery was dissected free of surrounding tissue just distal to the first diagonal branch. A pulsed Doppler flow probe (to measure coronary blood flow velocity) and snare occluder were then passed around the exposed section of artery.
For those animals entering the adenosine deaminase inhibition protocol, a 1 mg/ml solution of pentostatin (at neutral pH) was prepared on the day of the study by dissolving the compound in normal saline. Lidocaine was used in all animals to reduce the incidence of irreversible ventricular fibrillation during coronary artery occlusion, following the protocol of VanWinkle et al. (26) . Five minutes prior to the onset of occlusion animals received a slow 2 mg/kg lidocaine bolus followed by a continuous infusion of lidocaine (25 b~g/kg/min) throughout the occlusion. All drugs were administered intravenously through the jugular vein catheter.
Experimental protocol
After completion of the surgical preparation, animals were allowed 90 minutes to stabilize before being entered into one of three experimental groups. Group 1 (n = 6) underwent a 60 minute occlusion of the left anterior descending (LAD) artery. Group 2 (n = 6) was preconditioned prior to the 60 minute coronary occlusion with a single 10-min cycle of occlusion and reperfusion. Group 3 (n = 6) also underwent a 60-rain coronary occlusion, but it was preceded by the intravenous administration of 0.2 rag! kg of the adenosine deaminase inhibitor pentostatin (2-deoxycoformycin, Parke-Davis) 30-rain prior to the onset of occlusion. All pentostatin treated animals in this group were electrically paced to maintain heart rates at baseline levels throughout the protocol. At the completion of the coronary occlusion, all animals were reperfused for 3 h prior to infarct size determination.
Microdialysis
Measurement of local concentrations of interstitial adenosine, was achieved with microdialysis probes and HPLC analysis of the effluent (28) . As the perfusate passes slowly through the dialysis fiber (2/xl/min), diffusion occurs between the fluid in the fiber and the ISF surrounding it. Adenosine and other small molecules (MW < 5000) present in the ISF enter the dialysis fiber and are present in the collected dialysate. Thus, the concentration of a compound in the effluent (or dialysate) is representative of the intramyocardial ISF concentrations of that same substance. The ability to sample from the extracellular fluid using microdialysis provides a valuable tool by which alterations in ISF composition can be monitored during myocardial ischemia and reperfusion in the intact heart.
Probes were constructed using a single dialysis fiber (Clirans TH 10 hollow fiber dialysis tubing; 300 txm ID; wall thickness -5 b~m; molecular weight cutoff 5000) and hollow silica tubing (120 ~m ID, 170 txm OD; Scientific Glass Engineering, Austin, Texas). During the fabrication of each probe, a silica tube was inserted into each end of the dialysis fiber and adjusted such that the distance between the ends of the silica tubing was exactly one centimeter. The lengths of the inflow and outflow silica tubes were 15 and 30 cm respectively (28) . Previous in vitro data for this laboratory has demonstrated that this dialysis technique results in 70 % recovery of a 10 tzM adenosine solution at 37 ~ This in vitro recovery was determined by standard methods. Several fibers, similar to those used in vivo, were submerged in a polyethylene weigh boat containing a 10 ~M adenosine solution (in saline), glued in place, and perfused with a Krebs-Henseleit buffer at a rate of 2/xl/min. The dialysate was collected and the adenosine concentration determined by HPLC. The dialysate adenosine, expressed as a percentage of the bath concentration, is then referred to as the "in vitro percent recovery". However, the dialysate data in the present study were not corrected for in vitro recovery.
To place the microdialysis probe into the myocardium, the outflow silica tube was inserted into the lumen of a curved 25-gauge spinal needle. The needle was then passed through the left ventricular myocardium such that approximately 3 cm separated the entrance and exit sites on the surface of the heart. Once removed from the heart, the needle was slipped off the outflow silica tubing and the microdialysis probe was advanced through the myocardium until the dialysis fiber itself was positioned in the subendocardial layer of myocardium. Two probes were placed in the region at risk, and an additional probe was placed in the control region unaffected by LAD occlusion. After implantation all probes were flushed with KrebsHenseleit buffer and connected to a Harvard infusion pump. The Krebs-Henseleit buffer consisted of (in mM) 118.0 NaC1, 25.0 NaHCO3, 11.0 glucose, 4.7 KC1, 1.25 CaC12, 1.2 MgSO 4 9 7 H20 and 1.2 KH2PO 4.
To minimize the delivery of oxygen to ischemic myocardium through the dialysis fiber, 95 % N2-5 % CO2 was bubbled in the buffer until the PO2 of the solution was between 30 and 40 mmHg. The infusion system was rendered gas-tight through the use of Hamilton 2.5 ml gastight glass syringes and inert silica tubing leading to the dialysis fiber. Once connected to the infusion system, all probes were perfused with the Krebs-Henseleit buffer at a rate of 2 bd/min for the duration of the experiment. No samples were obtained for at least 90 min after implantation in order to allow for recovery of tissue injury incurred during the implantation process and the washout of any trauma-induced adenosine. At specified times in the protocol, effluent was collected from the outflow silica tube in a plastic microcentrifuge tube. Samples were frozen at -70 ~ and stored for later analysis by HPLC.
Analytical procedures
Samples were analyzed using reverse phase HPLC (Model 600E solvent delivery system; Waters Division of Millipore, Milford, MA). Separation of adenosine was achieved using a Supelcosil LC-18S column and a i % (pH 4.5) to 25 % (pH 5.3) methanol in 100 mM KH2PO4 gradient. Adenosine, inosine and hypoxanthine were detected by an absorbance change at 254 nm, and quantified by comparison to retention time and peak height of a known standard.
Infarct size determination
Infarct size was estimated in the animals who completed the protocol using a dual perfusion technique (11, 18) . At the end of the experimental protocol, the animal was euthanized with a saturated potassium chloride solution and the heart was excised. A cannula was inserted into the aorta and secured with a suture. The proximal LAD was ligated just above the occlusion site and a catheter was inserted and secured immediately distal to the point of ligation. The aorta was perfused retrogradely with a solution of 0.25 % Evans Blue, and the LAD was perfused with 4 % triphenyl tetrazolium chloride (TTC). Both solutions were infused simultaneously for 10 rain at a constant pressure of approximately 100 mmHg. Then the heart was removed from the perfusion apparatus and the atria, great vessels and right ventricle were cut away. The left ventricle was then sliced into six rings parallel to the minor axis. The anatomic area at risk was demarcated by the absence of Evans blue dye, and the TTC negative region representing irreversibly injured myocardium was indicated by the absence of red formazan precipitate. All rings were weighed for the subsequent determination of infarct size.
Both surfaces of the ventricular slices were photographed while they were immersed in water to eliminate highlights and color photographic slides were prepared. Slides were projected on a small screen, and traced onto a plastic overlay by hand. The tracings were scanned on a Microtek 600ZS scanner interfaced with a Macintosh Ilci computer. The percentage of each slice that was either infarcted or at risk was determined using the Image 1.22 m program.
Regional blood flow measurement
Although swine are reported to be a species lacking native coronary collateral circulation (14), 10 animals (three controls, four preconditioned, and three pentostatin treated) received injections of radiolabeled microspheres (15/xm diameter, New England Nuclear, Boston, Mass.) to measure regional myocardial blood flow and verify that the interventions we used did not change collateral perfusion. In control and preconditioned animals, microspheres were administered at baseline, 50 min after the onset of LAD occlusion, and 1 hour after reperfusion. Blood flow was determined in pentostatin treated animals at baseline, 30 rain after pentostatin administration, and at 50 min of ischemia. For each flow measurement, approximately 2 million microspheres (15 /xm diameter), labeled with one of four isotopes (Ce-141, Cr-51, Ru-103 or Nb-95, New England Nuclear), were injected into the left atrium using the reference withdrawal technique (4).
The reference arterial sample was withdrawn from the carotid artery at a constant rate, beginning before injection and ending 2 min after completion of the microsphere injection.
After completing infarct size determinations, the left ventricle slices were fixed in formalin for 24 h to facilitate sectioning. Tissue samples were obtained from each of the six rings and divided into subendocardial, midmyocardial, and subepicardial thirds. Samples were weighed and placed in Tracor (Model #1185) gamma scintillation counter. True counts were corrected for background counts. Blood flow was calculated using the equation: Qm = (Cm x Qr)/Cr where Qm = sample blood flow (ml/ min), Cm = cpm in tissue sample, Qr = reference sample flow rate (ml/min), and Cr = cpm in reference sample (4). Flows were normalized to ml/mirdg of tissue by dividing flow in each sample by the sample weight.
Data analysis
All data in the text and tables are reported as mean + SEM. Infarct and hemodynamic data (mean arterial and left atrial blood pressures, heart rate, dP/dt and ratepressure product) were evaluated using a one-way analysis of variance and Scheffe multiple comparison confidence intervals to detect group differences when appropriate. For comparison of values within each group over time, a repeated analysis of variance and the Scheffe test were used. A standard alpha level of p < 0.05 was used.
Dialysate adenosine data were evaluated using two different statistical procedures. Due to temporal differences in the protocols and the inability to make direct comparisons between groups at some time points, values obtained prior to the sustained coronary occlusion were compared to baseline values using a one-way repeated measures analysis of variance. After the onset of the sustained occlusion the time points for sample collection were identical in all groups, and therefore direct comparisons of values between groups were made using a one-way factorial analysis of variance and the Scheffe post-hoc test.
Exclusion criterion and animal use
All animals that exhibited intractable ventricular fibrillation during occlusion, requiring more than three attempts to convert with low energy (20-Joules) DC pulses into a normal sinus rhythm, were excluded from the study.
All animals included in this study were used in accordance with the guidelines of the American Physiological Society regarding the use of laboratory animals. The details of the protocol were reviewed, and approved by the Institutional Animal Care and Use Committee of the Park-Davis Pharmaceutical Research Division (approval number CV 069289).
Results

Mortality
Of the 30 animals entered into the study, 18 were included in the final data analysis. Five control animals, three preconditioned animals, and four pentostatin treated animals were excluded. Of these 12 exclusions, 11 were due to intractable ventricular fibrillation, and one due to surgical error. It should be noted that 83 % (25 out of 30) of the animals had at least one episode of ventricular fibrillation during the protocol. Of the animals included in the final data analysis, four control, three preconditioned and five pentostatin treated exhibited at least one episode of ventricular fibrillation, all occurring during the 60-rain coronary occlusions.
Hemodynamic data
Hemodynamic data are summarized in Table 1 . Although there was a general trend toward cardiac depression among all groups after the onset of the 60-min occlusion, the hemodynamic differences between groups were modest. A significant reduction in (+)dP/dt was observed in pentostatin treated animals when compared to control animals at baseline. This was the only statistically significant difference observed in the protocol.
Myocardial blood flow
The purpose of this portion of the protocol was to confirm the limited extent of collateral circulation in pigs, and to determine if preconditioning or adenosine deaminase inhibition altered myocardial perfusion during coronary occlusion. Microspheres were used in 10 animals (three controls, four preconditioned, and three pentostatin treated), and blood flows were calculated in bgth ischemic (region at risk) and nonischemic regions of myocardium. During baseline conditions there were no statistically significant differences among the three groups. In the pentostatin group, microspheres were administered to determine if this agent altered myocardial blood flow. No significant change in blood flow, however, was detected. In the ischemic area, coronary occlusion reduced blood flow to an average of 0.01 -0.02 ml/min/g in each group, confirming the near absence of collateral perfusion in the pig (14) , and demonstrating that preconditioning and pentostatin did not increase collateral blood flow. In the control and preconditioned groups, myocardial blood flow was measured 60 min after reperfusion. No statistically significant differences from baseline flow levels were observed. Blood flow was also measured in the nonischemic area. There was a tendency for perfusion to be lower during coronary occlusion and reperfusion, but no statistically significant differences were detected. The changes in the dialysate concentrations of adenosine occurring during ischemia and reperfusion are presented in Fig. 1 . This same data are plotted in Fig. 2 using a greatly reduced dialysate adenosine scale (y-axis) in order to illustrate some of the changes more clearly. Dialysate adenosine concentrations were not significantly different between groups at the end of the baseline equilibration period, averaging 0.67 + 0.1, 0.83 + 0.2 and 0.42 + 0.1/xM in the control, preconditioned, and pentostatin treated animals, respectively. The administration of pentostatin had no significant effect on dialysate adenosine prior to the onset of ischemia. The 10 min cycle of coronary occlusion and reperfusion used to induce preconditioning produced a transient sixfold increase in dialysate adenosine that was significant when compared to baseline. At the onset of the prolonged occlusion, adenosine concentrations in preconditioned animals remained slightly, but significantly, elevated when compared to baseline. Inhibition of adenosine deaminase with pentostatin produced a profound augmentation of dialysate adenosine during the prolonged occlusion. Adenosine concentrations were significantly higher in pentostatin treated animals at 20 min of occlusion, and remained significantly elevated until 60 min of reperfusion. The peak dialysate adenosine concentration in pentostatin treated animals (110.6 + 30.2/zM) occurred at 60 min of occlusion, a 100-fold increase compared to baseline (0.42 + 0.01 txM). In addition, this peak value was approximately sixfold higher then the peak observed in control animals (16.3 + 2.1 /xM), and over 25-fold greater then that in preconditioned animals (3.8 + 0.6/xM). It is interesting to note that in animals in which adenosine deaminase was inhibited, the dialysate adenosine concentrations continued to increase throughout the period of occlusion. In contrast, the peak adenosine concentrations in control and preconditioned animals occurred at 20 and 40 min of occlusion respectively, after which they began to decline.
The increase in dialysate adenosine observed during the occlusion was lower in preconditioned animals when compared to controls. The only time point however, during which this difference in dialysate adenosine reached statistical significance was at 10 rain of occlusion. At that time point, control dialysate adenosine was increasing dramatically, while concentrations in preconditioned animals were still declining following the initial occlusion and reperfusion.
Dialysate adenosine began to decline in all groups with the onset of reperfusion. Adenosine concentrations in pentostatin treated animals remained elevated somewhat longer in comparison to control and preconditioned animals, being significantly elevated until 40 rain of reperfusion. By lh of reperfusion, however, dialysate adenosine concentrations had returned to preischemic values in all groups. Figure 3 summarizes the changes observed in dialysate inosine concentrations. In untreated and preconditioned animals, inosine was the predominant metabolite that accumulated during ischemia. In control animals, a 60 min During the sustained occlusion the rise in inosine was attenuated in preconditioned animals, however, due to multiple group comparisons, statistical significance was not achieved. In pentostatin treated animals, adenosine, rather then inosine, was the primary purine metabolite to accumulate in the interstitium. Administration of pentostatin alone did not significantly alter inosine concentrations prior to ischemia. During ischemia, inhibition of adenosine deaminase resulted in a reduced accumulation of inosine. Dialysate inosine concentrations were significantly lower in pentostatin treated animals throughout the period of occlusion, reaching a peak value of 59 + 8/~M at 60 rain of ischemia. The onset of reperfusion resulted in a rapid decline in the inosine concentrations of all groups.
The changes in dialysate hypoxanthine concentrations in the exerimental groups are illustrated in Fig. 4 . The general hypoxanthine profile during ischemia and reperfusion was similar to that observed for inosine. Hypoxanthine concentrations in preconditioned animals were characterized by a significant increase during the preconditioning cycle, and reduced values during the early stages of the prolonged occlusion. Pentostatin treatment resulted in hypoxanthine concentrations that were markedly attenuated throughout the occlusion when compared to controls.
Infarct data
Infarct results are graphically summarized in 
Discussion
The objective of this study was to test the hypothesis that altering endogenous adenosine concentrations modifies ischemic tolerance, as defined by changes in infarct size. Adenosine levels increased during the 60-rain occlusion in control animals as anticipated and infarct size was approximately 35 % of the region at risk. When the 60-rain coronary occlusion was preceded by ischemic preconditioning, however, local adenosine concentrations were lower during the prolonged occlusion than in control animals despite being associated with substantial (> 75 %) infarct size reduction. The most striking change in microdialysate adenosine levels in these animals was evident during the 10-min preconditioning occlusion rather than the 60-rain occlusion. In the third group, the adenosine deaminase inhibitor pentostatin produced a pronounced augmentation in interstitial adenosine during the 60-min occlusion; the infarct size reduction associated with this elevation of endogenous adenosine was comparable to that observed with ischemic preconditioning. Thus, infarct size reduction was achieved with adenosine levels during the prolonged occlusion both higher and lower than those observed in control animals. The results with ischemic preconditioning suggest that the crucial change in adenosine levels occurred before the prolonged occlusion, during the brief interval of preconditioning ischemia. The pentostatin results suggest an altogether different interpretation: that dramatic elevations in local adenosine concentrations during the prolonged occlusion are just as effective as preconditioning in reducing infarct size. The interstitial nucleoside concentrations measured in preconditioned animals appear to support the conclusions of Murry et al. (17) . Reporting direct tissue measurements of ATP and metabolic intermediates, the authors hypothesized that preconditioning slows metabolism and energy utilization in the ischemic heart. Consistent with this notion, Van Wylen et al. recently published a study examining the effect of ischemic preconditioning on the changes in ISF adenosine during ischemia in an alphachloralose anesthetized canine model (27) . ISF adenosine was reported to increase approximately 10-fold in myocardium subjected to 60 min of regional ischemia. Alternatively, hearts preconditioned with two successive 5 rain occlusions and 10 min of reperfusion exhibited reduced accumulation of adenosine during the sustained occlusion. In the present study dialysate adenosine in the ischemic myocardium increased from 0.7 + 0.1 to 16.3 + 2.1/xM in control pigs. Preconditioned animals demonstrated attenuated increases in dialysate adenosine during the same 60-rain occlusion, reaching a peak value of only 3.8 + 0.6/~M, Thus, our results are qualitatively similar to those obtained by Van Wylen (27) , and indicate that preconditioning attenuates adenosine accumulation during subsequent myocardial ischemia.
If the actions of adenosine are beneficial to the ischemic myocardium, they unfortunately are short lived. Adenosine has a half-life on the order of 1.5 s in human plasma (23) . Two divergent pathways are involved in the metabolism of adenosine. Rephosphorylation by adenosine kinase to AMP is favored at low adenosine concentrations (Km = 0.4 -6.0 nM). As adenosine levels increase, its deamination and conversion to inosine by adenosine deaminase is the preferred reaction (Km = 16-400 t~M) (23) . In addition, adenosine available in the extracellular compartment is rapidly transported across the cell membrane into the cell via the nucleoside transporter. Through these metabolic and reuptake pathways, adenosine produced during ischemia has a limited time to exert its protective effects.
Adenosine is enzymatically deaminated and converted to inosine by adenosine deaminase. By inhibiting this enzyme, the breakdown of adenosine is minimized, thereby supporting local concentrations of the nucleoside. Pentostatin (2-deoxycoformycin) is a potent inhibitor of adenosine deaminase. It is a stable molecule that binds the transition state intermediate of the deamination reaction of adenosine to inosine; effectively binding and inhibiting adenosine deaminase. The compound has a picomolar affinity (Ki = 2.5 • 10 -12) for adenosine deaminase, and is bound by the enzyme six to eight orders of magnitude more tightly than its native substrate adenosine (9, 29) . It should also be noted that a 10-fold increase in adenosine observed with adenosine deaminase inhibition does not necessarily correspond to a 10-fold reduction in inosine concentrations. Just as there is redundancy to the pathways involved in adenosine formation, there are several pathways involved in inosine formation. Even with complete adenosine deaminase inhibition, inosine can be produced by the dephosphorylation of inosine monophosphate by 5' nucleotidase.
Such an inhibitor of adenosine deaminase could substantially augment the rise in interstitial adenosine that occurs during myocardial ischemia. Indeed, in the present study, dialysate adenosine concentrations obtained during the 60-rain LAD occlusion were over sixfold higher in pentostatin treated animals when compared to untreated controls (110.6 + 30.2 vs. 16.3 + 2.1 txM). By increasing or prolonging the elevation in regional adenosine during ischemia, it may be possible to augment the protective effects of adenosine in ischemic myocardium.
Several studies indicate that inhibitors of adenosine deaminase can be protective in the setting of myocardial ischemia. Examination of the existing literature indicates that the efficacy of adenosine deaminase inhibitors to reduce ischemic injury greatly depends upon the model and endpoint evaluated. Several recent studies, from this and other laboratories, have indicated that adenosine deaminase inhibition can attenuate myocardial stunning, measured in terms of improved regional ventricular function, following brief regional ischemia in the dog (1, 3, 15) . Improved global function following global ischemia has been reported with adenosine deaminase inhibition in the isolated guinea pig (19) and rat heart (32) , and a canine model of cardiopulmonary bypass (6). Furthermore, studies have demonstrated that inhibition of adenosine deaminase reduced net high energy phosphate degradation, and improved post-ischemic recovery of adenine nucleotide content (19, 30) . Although these studies show improvement in a non-necrosis model of ischemia and reperfusion, they suggest a protective role of pentostatin in myocardial ischemia.
In none of the previously mentioned studies was the administration of adenosine deaminase inhibitors evaluated in terms of its ability to modify the irreversible injury associated with prolonged myocardial ischemia. While the direct administration of exogenous adenosine has been demonstrated to reduce infarct size (25, 31) , and the administration of adenosine deaminase has been shown to eliminate the infarct reducing effects of preconditioning (20) , the use of an adenosine deaminase inhibitor has been examined using this endpoint in few studies. In 1993, Li et al. (12) observed that administration of the adenosine deaminase inhibitor EHNA failed to reduce infarct size in the rat. However, the authors reported no ISF or tissue nucleosides data. Silva et al. (22) recently reported that in a canine regional ischemia model, pentostatin (0.2 mg/kg) resulted in a marked increase in interstitial adenosine concentrations. Their nucleoside measurements, obtained using the microdialysis technique, compare very well, both qualitatively and quantitatively, to those obtained in the present study. However, in sharp contrast to the present study, the authors observed no reduction in the development of myocardial infarction in pentostatin treated dogs. In addition to the possible species specific diffferences, the authors suggested another possibility to explain inability of pentostatin to reduce infarct size in their model. They suggested that the release of adenosine from the ischemic region into the systemic circulation at reperfusion may be responsible for the observed hypotension and pronounced increase in circumflex blood flow that occurred during early reperfusion in pentostatin treated animals. The combination of peripheral hypotension and increased circumflex flow may limit reactive hyperemia in the ischemic region during the early phase of reperfusion. Since no measurements of early reperfusion blood flow or arterial adeimsine concentrations were made in the present study, it is difficult to determine what role, if any, this pentostatin induced "steal" may have had in our swine model.
There are some methodological limitations of the present study that should be addressed. First, there is a possibility of direct adenosine receptor activation by pentostatin itself. As stated earlier, pentostatin is structurally very similar to a transition state compound in the conversion of adenosine to inosine. In light of this structural similarity, it is possible that pentostatin exerted its protective effects through preischemic adenosine receptor activation in addition to augmentation of interstitial adenosine concentrations during ischemia. If the cytoprotective actions of adenosine are receptor mediated, then activation of the receptor by pentostatin could be protective. This possibility is supported by the fact that a reduction in heart rate was observed shortly after the administration of pentostatin. Although reversing this effect with atrial pacing did not eliminate the observed reduction in infarct size, it provfdes evidence for possible At adenosine receptor activation at the SA node. Conversely, the observed reduction in heart rate could also be the resulf of subtle increases in adenosine concentrations following inhibition of adenosine deaminase.
Secondly, in the present study there was no radioactive microsphere determination of myocardial blood flow during early reperfusion. During coronary artery occlusion in the presence of adenosine deaminase inhibition, a marked rise in interstitial adenosine is observed. Upon reperfusion, this adenosine is washed out and may augment coronary blood flow during the hyperemia. It is conceivable that this increase in early reperfusion flow may be protective. Our final microsphere injection was made at approximately 1 h of reperfusion, when blood flow had stabilized to near baseline levels. This provides a means of comparing reperfusion flows between animals and groups, independent of excessive variations due to the accumulation of metabolic factors and reactive hyperemia_
The admir~istratiar~ of lidocaine is essential in ischemia studies in swine to reduce the incidence of ventricular fibrillation during the sustained occlusion. Its use however, could be viewed as a confounding variable since Homeister et al. (5) reported that the protective effects of exogenous adenosine administered at reperfusion were only observed in the presence of lidocaine. However, several studies have reported that the infarct reducing effects of preischemic adenosine are not dependent upon tidocaine (t0, 24, 31) . When combined with the facI that the present study augments endogenous adenosine (as opposed to administration of exogenous adenosine), these data suggest that the protective effects of pentostatin are not dependent upon lidocaine.
Lastly, there is a possibility that a reduction in body temperature may also be a factor in the observed reduction in infarct size. In a recent study from our laboratory, McClanahan et al. (16) reported that the infarct limiting effects of pentostatin were significant only when combined with mild hypothermia; mild hypothermla was characterized as 35 -36 ~ According to that definition, the majority of animals in the present study would be characterized as "mildly hypothermic". Despite the use of a water recirculating heating blanket, and other efforts to minimize heat loss, a slight decrease in body temperature was unavoidable in this open-chest preparation.
In conclusion, the present study provides evidence that inhibitior~ of adenosine deaminase with pentostatir~ can significantly augment local adenosine concentrations in ischemic myocardium. Pentostatin also reduces the extent of irreversible myocardial injury resulting from prolonged ischemia. The degree of protection is similar to that derived from ischemic preconditioning, and is not mediated by the negative chronotropic actions of the drug.
